| abstract |
the invention relates to heterocyclic compounds of formula (i) and pharmaceutically acceptable salts thereof. the use of such heterocyclic compounds and pharmaceutically acceptable salts thereof for the treatment of cancers, and more particularly cancers sensitive to inhibition of mitochondrial activity and increased levels of reactive oxygen species (ros), is also disclosed. such cancers include acute myeloid leukemia (aml), preferably aml characterized by certain traits, such as high expression level of one or more homeobox network (hox) genes, high and / or low expression of specific genes, the presence of one or more more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, normal karyotype (a / k), mutated npmi, mutated cebpa, mutated flt3, mutated dnmt3a, mutated tet2, mutated idh1, mutated idh2, mutated runx1, mutated wt1, mutated srsf2 , intermediate cytogenetic risk with abnormal karyotype (intern (abnk)), trisomy 8 (+8) and / or abnormal chromosome (5/7) and / or high leukemic stem cell (lsc) frequency. |